Monitoring measurable residual disease with multigene mutations ddPCR combined with multiparametric flow cytometry to predict relapse risk in patients with acute my-eloid leukemia
10.12354/j.issn.1000-8179.2025.20250782
- VernacularTitle:多突变基因数字PCR联合多参数流式细胞术监测可检测残留病预测急性髓系白血病患者复发风险
- Author:
Ye SHAOJIE
1
;
Guo HUIMEI
1
;
Xu JIANMEI
1
;
Su XI
1
;
Wang LIN
1
;
Zhao SONGYING
1
;
Wang JING
1
;
Xue HUA
1
Author Information
1. 河北大学附属医院血液科(河北省 保定市 071000)
- Publication Type:Journal Article
- Keywords:
measurable residual disease(MRD);
droplet digital PCR(ddPCR);
multiparametric flow cytometry(MFC);
relapse;
intensive chemotherapy;
acute myeloid leukemia(AML)
- From:
Chinese Journal of Clinical Oncology
2025;52(15):762-768
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the prognostic value of droplet digital PCR(ddPCR)in conjunction with multiparametric flow cytometry(MFC)for measurable residual disease(MRD)detection in predicting relapse risk in patients with acute myeloid leukemia(AML).Methods:In this retrospective cohort study,we have analyzed 78 newly diagnosed patients with AML who underwent combined MRD monitoring using MFC and ddPCR at The Affiliated Hospital of Hebei University(January 2018-January 2025).Clinical outcomes-including MRD negativity rates,cumulative incidence of relapse(CIR),relapse-free survival(RFS),and overall survival(OS)-were systematically evaluated.Prognostic discrim-ination between the MRD-negative and MRD-positive subgroups was compared across standalone and combined detection approaches.Results:With a median follow-up of 17 months(range:2.4-86.7)and a median of one mutation tracked per patient(range:1-3),both MFC-MRD and ddPCR-MRD negative subgroups demonstrated superior 2-year RFS compared with MRD-positive counterparts.Notably,com-bined MFC/ddPCR monitoring enhanced prognostic discrimination,with MRD-negative patients achieving significantly prolonged 2-year RFS compared with MRD-positive patients.MFC-MRD negativity independently predicted improved 2-year OS.Conclusion:ddPCR-based multi-gene MRD profiling provides significant independent prognostic value in patients with AML.The synergistic application of MFC and ddPCR enables superior predictive accuracy for relapse risk and survival outcomes,supporting its integration into standardized MRD monitoring protocols.
